Last updated: 2026-09-17 00:06:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Yarrow Bioscience, Inc. (YARW) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $26.30, with a market capitalization of $70.11M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $24.58 to $44.28. This page covers its latest market performance, valuation, price trends and company information.
$70.11M | |
$25.38 | |
$44.28 | |
$24.58 | |
$25.50 | |
60.53K | |
73.47K | |
-- | |
$44.28 | |
$24.58 | |
-- | |
-- |
Yarrow Bioscience, Inc. (YARW) last closed at $25.50 as of 2026-09-16 23:31:00, unchanged from the previous close of $25.50.
During the latest regular trading session, YARW traded between $24.58 and $44.28, with a volume of 60.53K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Yarrow Bioscience, Inc. (YARW) moved from $30.21 to $26.30, representing a decline of 12.93% ($3.91).
The stock traded between $24.58 and $33.73 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 239.08 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 8.7%
YARW is currently trading at $26.30, placing it 8.7% of the way from its 52-week low of $24.58 to its 52-week high of $44.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Yarrow Bioscience, Inc. (YARW) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.